Corvus Pharmaceuticals Inc (CRVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.043x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.37 Million) by net assets ($240.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Corvus Pharmaceuticals Inc (CRVS) balance sheet quality index to measure how much of total assets are equity-financed.
Corvus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Corvus Pharmaceuticals Inc (CRVS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ennostar Inc
TW:3714
|
0.016x |
|
Gentherm Inc
NASDAQ:THRM
|
-0.007x |
|
Ningbo Changhong Polymer Scientific & Technical Inc
SHG:605008
|
-0.082x |
|
Fusheng Precision Co Ltd
TW:6670
|
0.068x |
|
VERBIO Vereinigte BioEnergie AG
XETRA:VBK
|
-0.023x |
|
Tarkett SA
PA:TKTT
|
-0.097x |
|
Brainbees Solutions Limited
NSE:FIRSTCRY
|
-0.009x |
|
NanJi ECommerce Co Ltd
SHE:002127
|
0.029x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Corvus Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.20 Million | $-32.80 Million | -0.536x | +31.36% |
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more